30 September 2024
30 September 2024
The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.
Bavarian Nordic has already said it would prioritise mpox vaccine production to fulfil orders this year.
With an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.
Dupixent has gained positive opinions from KOLs due to the positive data presented from the asset’s two Phase III clinical trials.
The NDA submission is backed by results from a study that enrolled 604 adults from China who have stable plaque psoriasis.
The new plant will house eight production lines with an annual capacity of tens of tonnes.
The FDA placed a full clinical hold on two diabetes trials for Biomea’s menin inhibitor after reports of liver toxicity.
Is the pharma industry ready to realise blockchain tech’s potential in tackling counterfeit drugs?
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Per our analysis, drug sales in the COPD drug market is expected to grow at a steady rate between 2023 and 2033, with an overall CAGR of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. Key topics covered in the report include an assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.
Per our analysis, drug sales in the COPD drug market is expected to grow at a steady rate between 2023 and 2033, with an overall CAGR of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. Key topics covered in the report include an assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.
Per our analysis, drug sales in the COPD drug market is expected to grow at a steady rate between 2023 and 2033, with an overall CAGR of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. Key topics covered in the report include an assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.
Per our analysis, drug sales in the COPD drug market is expected to grow at a steady rate between 2023 and 2033, with an overall CAGR of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. Key topics covered in the report include an assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.
Per our analysis, drug sales in the COPD drug market is expected to grow at a steady rate between 2023 and 2033, with an overall CAGR of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. Key topics covered in the report include an assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.
Give your business an edge with our leading industry insights.
